

May 12, 2022



To

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

Tel: 022 - 2272 1233 /4

Fax: 022 - 22721919

Ref: Aragen Life Sciences Private Limited

Scrip Code: 973783

ISIN: INE483I07010

Sub: Statement indicating the utilization of issue proceeds of the non-convertible debt securities under Regulation 52(7) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


Dear Sir/Mam,

Pursuant to Regulation 52(7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that the proceeds from the non-convertible debt Securities issued by the Company during the quarter ended March 31, 2022, aggregating to ₹200,00,00,000 (Rupees Two Hundred Crores Only), have been fully utilised on the objects specified in the Placement Memorandum of the issue as mentioned below and there has been no deviation/variation in the use of proceeds.

S.No	Objects	Original Allocation of funds (INR Crores)	Funds Utilised (INR Crores)
1	Financing/ refinancing/ reimbursement of the capex incurred by the Company	125	125
2	Financing/refinancing the consideration payable for acquisitions by the company and general corporate purposes	75	75
	Total	200	200

Kindly take the same on your records.

For Aragen Life Sciences Private Limited


Ramakrishna Kasturi
Company Secretary & Compliance Officer



Registered & Corporate Office
Aragen Life Sciences Pvt. Ltd.
(Formerly known as GVK Biosciences Pvt. Ltd.)
28 A, IDA Nacharam, Hyderabad 500 076, India
T: +91 40 6692 9999 F: +91 40 6692 9900
W: aragen.com CIN: U74999TG2000PTC035826